Investor
Board of Directors
The board of directors holds overall responsibility for the company’s management and strategy. The board is structured to ensure independent operation while addressing the collective interests of all shareholders while meeting the company’s needs for expertise, capacity and diversity.
Morten Foros Krohnstad
Chair of the Board & Chair of the Remuneration Committee
Year of birth: 1968
Elected: 2020
Number of shares: 1 600 000
Field of expertise: Corporate law and corporate strategy
Morten Krohnstad is a partner in the law firm Schjødt and has extensive experience as a business lawyer and serves on several boards in Norwegian listed and un-listed companies. Krohnstad has a master’s in law from the University of Bergen, Norway.
Renete Kaarvik
Member of the Board & Chair of the Audit Committe
Year of birth: 1974
Elected: 2026
Number of shares: 0
Field of expertise: Finance
Renate Kaarvik has 25 years of experience from various positions within corporate finance, auditing and advisory services. She has broad experience from group finance positions in companies listed on Oslo Børs, including Grieg Seafood ASA and Marine Harvest ASA (now Mowi ASA). Until April 2026, she held the position as CFO in Lifecare ASA. Kaarvik recently assumed the position as Deputy MD of Lingalaks AS. Kaarvik holds a master’s degree in applied finance from Macquarie University in Sydney, Australia and a Master of Science in business.
Hans Johan Hekland
Member of the Board & member of the Audit Committee
Year of birth: 1958
Elected: 2021
Number of shares: 1 451 498
Field of expertise: Business development, strategy and finance
Hans Hekland is a managing partner in Sarsia Venture Management. He has extensive experience from board positions and involvement in the medical development companies and other listed and unlisted companies. He has broad expertise from fund management, strategy, business development and finance. Hekland holds a master of science in economics and business administration from the Norwegian School of Management, Bergen, Norway.
Kathrine Gamborg Andreassen
Member of the Board
Year of birth: 1966
Elected: 2026
Number of shares: 0
Field of expertise: MedTech and pharma business
Kathrine Gamborg Andreassen holds the position as CEO in Navamedic ASA. Before assuming her current role, she has served as Chair of the Board at Navamedic ASA in 2018. Prior to joining Navamedic, she held several senior leadership positions at Weifa ASA, including CEO. She has previously served on the board of directors at Observe Medical, Questback and Vistin Pharma. Gamborg Andreassen holds a master’s degree (MSc) in Business Strategy & Marketing from the University of Wisconsin at Madison and a BBA from Oslo Business School.
Tore Birger Ellingsen
Member of the Board
Year of birth: 1958
Elected: 2026
Number of shares: 0
Field of expertise: Strategy devolment, product innovation, risk management and capital efficiency
Tore B. Ellingsen has over 35 years’ experience in the insurance and banking sectors, as well as in the chemical and pharmaceutical industries. He was the founder and managing partner of inea GmbH. Ellingsen has broad experience from senior positions within the banking, insurance and consultancy sectors. Currently he holds a position as Chair of the Board at Gabler AS. Ellingsen holds an MBA with a specialisation in banking, insurance and psychology from the University of Mannheim in Germany.
Group management
The Group management team is responsible for overseeing the company’s daily operations, ensuring alignment with its strategic goals.
Joacim Holter
Chief Executive Officer
Year of birth: 1976
In position since: 2020
Number of shares: 704 256
Joacim Holter has close to 20 years of management experience, including six years’ experience leading international R&D and product development based in Switzerland. He has broad experience from board positions including as chairman and later member of the Lifecare Board of Directors from 2011 to 2020. He has also managed his own lawyer practice for 16 years. Holter holds a master’s in law from the University of Bergen, Norway.
Petter Nielsen
Chief Financial Officer
Year of birth: 1979
In position since: 2026
Number of shares: 0
Petter Nielsen has more than 20 years of experience from various management positions primarily with financial focus. Most recently he served as CEO of Gexcon where he also previously held the position as CFO. He also has experience from the life sciences sector having served as CFO of BerGenBio. During his tenure at BerGenBio, the company went through the process of IPO and listing on the Oslo Stock Exchange, conducted multiple rounds of financing, secured public grants, and carried out several international clinical trials. Nielsen holds an MSc in Auditing and an MSc in Economics and Business Administration from the Norwegian School of Economics (NHH).
Nomination committee
Lifecare’s nomination committee has three members elected at the annual general meeting. The nomination committee’s work is carried out in accordance with instructions adopted by the general meeting. The duties of the nomination committee are to present recommendations to the general meeting on candidates for election to the board of directors and for the nomination committee.
The members of the nomination committe, elected in the annual general meeting in April 2024, are Christian Hysing-Dahl, Marthe Jansen and Oddvar Kaarbø. Proposals for new candidates to the board of directors or the nomination committee can be submitted to the nomination committee leader Christian Hysing-Dahl: chd@hantri.no.
Scientific advisory board
Lifecare has a scientific advisory board, which consists of highly reputable experts within diabetes technology, clinical medicine, endocrinology, physics and nanotechnology. The chair of the scientific advisory board is Prof. David Klonoff, an endocrinologist specializing in the development and use of diabetes technology.
General meetings
Shareholders are the owners of the company, and the general meeting serves as the company’s supreme governing body. The annual general meeting is held by 30 June each year, while extraordinary meetings are called when necessary to address specific matters. Notices and supporting documents will be published on the company’s website at least 21 days before the meetings.
Event
Annual General Meeting
Apr 23, 2026
Extraordinary General Meeting
Jan 2, 2026
Lifecare ASA will hold an Extraordinary General Meeting in connection with the partially underwritten rights issue of NOK 80–100 million. The meeting will address:
– Share capital increase
– Issuance of warrants (Series 1 & 2)
– Board authorization for underwriting fee shares
– Issuance of additional warrants (Series 1 & 2)
Nominee-registered shareholders wishing to participate in the Extraordinary General Meeting must notify the Company no later than two business days before the meeting, i.e. by the end of 30 December 2025, cf. section 5-3 of the Norwegian Public Limited Companies Act.
Extraordinary General Meeting
Nov 12, 2025
In order to facilitate the subscription of shares and exercise of warrants in connection with the contemplated partially underwritten rights issue announced by the Company on 22 October 2025, the Board proposes that the General Meeting resolves to reduce the par value of the Company’s shares to NOK 0.10.
Nominee-registered shareholders wishing to participate in the Extraordinary General Meeting must notify the Company no later than two business days before the meeting, i.e. by the end of 10 November 2025, cf. section 5-3 of the Norwegian Public Limited Companies Act.
Annual General Meeting
Apr 24, 2025
Extraordinary General Meeting
Sep 17, 2024
For the planned uplisting from Euronext Growth Oslo to Oslo Børs, a share consolidation is required to meet the NOK 10 per share listing requirement. Additionally, to address shareholders with fractional shares post-consolidation, the Board proposes General Meeting’s approval to acquire treasury shares.
Extraordinary General Meeting
May 16, 2024
The Board proposes that the extraordinary general meeting resolves to increase the Company’s share capital by a partially underwritten rights issue. In order to create an incentive for subscriptions in the Rights Issue, the Board proposes issuance of warrants.
Annual General Meeting
Apr 30, 2024
Annual General Meeting
Apr 18, 2023
Annual General Meeting
May 6, 2022
Documents & policies
The corporate governance framework ensures accountability, fairness, and transparency in our relationship with stakeholders, including shareholders, management, employees and the broader community.
